These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. The role of stem cells in aesthetic surgery: fact or fiction? McArdle A; Senarath-Yapa K; Walmsley GG; Hu M; Atashroo DA; Tevlin R; Zielins E; Gurtner GC; Wan DC; Longaker MT Plast Reconstr Surg; 2014 Aug; 134(2):193-200. PubMed ID: 24732654 [TBL] [Abstract][Full Text] [Related]
45. Conditional Approvals for Autologous Stem Cell-Based Interventions: Lee TL; Lysaght T Perspect Biol Med; 2018; 61(1):59-75. PubMed ID: 29805148 [TBL] [Abstract][Full Text] [Related]
46. An overview of Food and Drug Administration regulation of drugs, biologics, and devices to be used for management of periodontal diseases. Tylenda CA; Weintraub M Ann Periodontol; 1997 Mar; 2(1):11-7. PubMed ID: 9151539 [TBL] [Abstract][Full Text] [Related]
47. Athletes' use of unproven stem cell therapies: adding to inappropriate media hype? Caulfield T; McGuire A Mol Ther; 2012 Sep; 20(9):1656-8. PubMed ID: 22945228 [No Abstract] [Full Text] [Related]
48. Characterizing Direct-to-Consumer Stem Cell Businesses in the Southwest United States. Frow EK; Brafman DA; Muldoon A; Krum L; Williams P; Becker B; Nelson JP; Pritchett A Stem Cell Reports; 2019 Aug; 13(2):247-253. PubMed ID: 31378670 [TBL] [Abstract][Full Text] [Related]
50. Human embryonic stem cell lines: socio-legal concerns and therapeutic promise. McLaren A C R Biol; 2002 Oct; 325(10):1009-12. PubMed ID: 12494497 [TBL] [Abstract][Full Text] [Related]
51. Unproven but Profitable: The Boom in US Stem Cell Clinics. Rubin R JAMA; 2018 Oct; 320(14):1421-1423. PubMed ID: 30326510 [No Abstract] [Full Text] [Related]
52. Current state of Health Canada regulation for cellular and gene therapy products: potential cures on the horizon. Chisholm J; Ruff C; Viswanathan S Cytotherapy; 2019 Jul; 21(7):686-698. PubMed ID: 31196821 [TBL] [Abstract][Full Text] [Related]
53. How are drugs approved? Part 1: the evolution of the Food and Drug Administration. Howland RH J Psychosoc Nurs Ment Health Serv; 2008 Jan; 46(1):15-9. PubMed ID: 18251347 [TBL] [Abstract][Full Text] [Related]
54. The action behind the words: embryonic stem cell research marches on. Leslie M J Cell Biol; 2006 Sep; 174(6):743-6. PubMed ID: 16966416 [TBL] [Abstract][Full Text] [Related]
55. Missing data issues at the FDA Center for Biologics Evaluation and Research. Scott JA; Hsu H J Biopharm Stat; 2011 Mar; 21(2):196-201. PubMed ID: 21390996 [TBL] [Abstract][Full Text] [Related]
56. The deadly business of an unregulated global stem cell industry. Lysaght T; Lipworth W; Hendl T; Kerridge I; Lee TL; Munsie M; Waldby C; Stewart C J Med Ethics; 2017 Nov; 43(11):744-746. PubMed ID: 28356490 [TBL] [Abstract][Full Text] [Related]
57. Stem-cell therapy takes off in Texas. Cyranoski D Nature; 2012 Feb; 483(7387):13-4. PubMed ID: 22382952 [No Abstract] [Full Text] [Related]
59. From bench to FDA to bedside: US regulatory trends for new stem cell therapies. Knoepfler PS Adv Drug Deliv Rev; 2015 Mar; 82-83():192-6. PubMed ID: 25489841 [TBL] [Abstract][Full Text] [Related]